Tilray Brands (NASDAQ:TLRY – Get Free Report) and Pfizer (NYSE:PFE – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Tilray Brands and Pfizer’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tilray Brands | -16.91% | -10.39% | -7.38% |
| Pfizer | 6.34% | 19.88% | 8.52% |
Earnings and Valuation
This table compares Tilray Brands and Pfizer”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tilray Brands | $915.45 million | 0.39 | -$121.40 million | ($1.40) | -1.74 |
| Pfizer | $62.58 billion | 2.63 | $7.77 billion | $0.70 | 41.27 |
Pfizer has higher revenue and earnings than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Tilray Brands has a beta of 2.04, indicating that its stock price is 104% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.31, indicating that its stock price is 69% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Tilray Brands and Pfizer, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tilray Brands | 2 | 2 | 3 | 1 | 2.38 |
| Pfizer | 2 | 14 | 6 | 0 | 2.18 |
Tilray Brands currently has a consensus target price of $5.90, suggesting a potential upside of 142.80%. Pfizer has a consensus target price of $30.32, suggesting a potential upside of 4.95%. Given Tilray Brands’ stronger consensus rating and higher possible upside, equities analysts plainly believe Tilray Brands is more favorable than Pfizer.
Insider and Institutional Ownership
9.3% of Tilray Brands shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.6% of Tilray Brands shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Pfizer beats Tilray Brands on 10 of the 15 factors compared between the two stocks.
About Tilray Brands
Tilray Brands is a global cannabis and consumer packaged goods company. Its cannabis business produces and sells medical and adult-use products, including dried flower, oils, extracts and edibles, under brands such as Good Supply, Solei, Redecan and Broken Coast. The company serves customers in Canada, the United States and international markets. Its activities include medical cannabis distribution in countries where permitted, as well as cannabis and hemp-related products in North America, subject to local regulations.
About Pfizer
Pfizer Inc. is a global biopharmaceutical company that researches, develops, manufactures and commercializes prescription medicines and vaccines. Its work spans areas including oncology, vaccines, internal medicine, inflammation and immunology, rare diseases, and infectious diseases. The company’s products include the Prevnar family of vaccines and medicines such as Eliquis, which it commercializes with Bristol Myers Squibb, and Paxlovid. Pfizer also developed the Comirnaty COVID-19 vaccine with BioNTech.
Receive News & Ratings for Tilray Brands Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray Brands and related companies with MarketBeat.com's FREE daily email newsletter.
